1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985; 103:1796–806.
2. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology. 1987; 94:761–74.
3. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline : ETDRS report no. 19. Arch Ophthalmol. 1995; 113:1144–55.
4. Martidis A, Duker JS, Greenberg PB. . Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002; 109:920–7.
Article
5. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980; 90:810–6.
Article
6. Aiello LP, Avery RL, Arrigg PG. . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl JMed. 1994; 331:1480–7.
Article
7. Funatsu H, Yamashita H, Ikeda T. . Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003; 110:1690–6.
Article
8. Funatsu H, Yamashita H, Ikeda T. . Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2002; 133:537–43.
Article
9. Haritoglou C, Kook D, Neubauer A. . Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006; 26:999–1005.
Article
10. Audren F, Lecleire-Collet A, Erginay A. . Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006; 142:794–9.
Article
11. Jonas JB. Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev Ophthalmol. 2007; 39:96–110.
Article
12. Massin P, Audren F, Haouchine B. . Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004; 111:218–24.
13. Floman N, Zor U. Mechanism of steroid action in ocular inflammation: inhibition of prostaglandin production. Invest Ophthalmol Vis Sci. 1977; 16:69–73.
14. Wilson CA, Berkowitz BA, Sato Y. . Treatment with ntravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992; 110:1155–9.
15. Schindler RH, Chandler D, Thresher R, Machmer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982; 93:415–7.
Article
16. Beer PM, Bakri SJ, Singh RJ. . Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003; 110:681–6.
Article
17. Gillies MC, Simpson JM, Billson FA. . Safety of intravitreal injection of triamcinolone. Arch Ophthalmol. 2004; 122:336–40.
18. Strom C, Sander B, Klemp K. . Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci. 2005; 46:3855–8.
19. Arevalo JF. . Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007; 114:743–50.
20. Chun DW, Heier JS, Topping TM. . A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006; 113:1706–12.
Article
21. Ahmadieh H, Ramezani A, Shoeibi N. . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2008; 246:483–9.
22. Paccola L, Costa RA, Folgosa MS. . Intravitreal Triamcinolone versus Bevacizumab for treatment of Refractory Diabetic Macular Edema (IBEME study). Br J Ophthalmol. 2008; 92:76–80.
23. Audren F, Lecleire-Collet A, Erginay A. . Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006; 142:794–9.
Article